(Bloomberg) — Sanofi is studying potential acquisitions of U.S. biotechnology companies including Principia Biopharma Inc. as it seeks innovative treatments for clinical areas including multiple sclerosis and immune disorders, people with knowledge of the matter said.The French drugmaker is working with advisers to study potential deals, the people said, asking not to be identified because the information is private.Chief Executive Officer Paul Hudson, who joined last year, is seeking to rejuvenate Sanofi by focusing on fast-growing areas where new medicines command high prices. There’s no certainty the deliberations will lead to a transaction, according to the people.Sanofi shares were little …read more
Source:: Yahoo Finance
